CorMedix (CRMD) investor relations material

Business overview and strategy

• Focuses on innovative specialty injectable therapies for institutional markets, with a scalable commercial platform and diversified product portfolio, including eight products such as DefenCath and REZZAYO.

• Revenue guidance for 2026 is $325–345 million, with adjusted EBITDA of $115–135 million, and high visibility into revenue streams.

• Growth driven by pipeline expansion, label extensions, and government partnerships, with bolt-on acquisition capability.

• Products are sold to over 500 hospitals, infusion centers, and clinics, supported by an integrated commercial team.

Leadership and financials

• Leadership team has a strong track record in commercial execution and drug development, with experience from major pharma and biotech firms.

• As of March 31, 2026, cash and short-term investments total $178 million, with $150 million in convertible debt.

• FY 2025 pro forma net revenue was $401 million; Q1 2026 net revenue was $127 million, with DefenCath sales at $98 million.

• Sustained profitability and financial flexibility enable pursuit of business development opportunities.

Product portfolio and market position

• Portfolio includes DefenCath (catheter lock solution), REZZAYO (once-weekly echinocandin), Minocin, Vabomere, Kimyrsa, Orbactiv, Baxdela, and Toprol-XL.

• DefenCath is the first FDA-approved catheter lock solution reducing CRBSI risk, with strong uptake in outpatient dialysis and agreements covering ~60% of the market.

• Real-world evidence shows DefenCath reduces CRBSI by 72% and related hospitalizations by 70%.

• REZZAYO offers once-weekly dosing for candidemia and invasive candidiasis, with strong formulary adoption and patent protection through 2038.

• Minocin, Vabomere, and the oritavancin franchise are differentiated anti-infectives with robust IP coverage and growing revenues.